← All trials
NCT03082014
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2017
- Primary completion
- Sep 30, 2019
- Completion date
- Sep 30, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 105
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Ludwig Maximilians UniversityLead sponsor
- Maastricht UniversityOverall official - principal investigator
- Utrecht UniversityOverall official - principal investigator
- University of EdinburghCollaborator
- Utrecht UniversityCollaborator
- Maastricht UniversityCollaborator
- University of OxfordOverall official - principal investigator
- University of OxfordCollaborator
- Ludwig Maximilians UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.